AFT introduces new HYLO-FRESH and HYLO-FORTE

AFT Pharmaceuticals is pleased to announce the launch of new HYLO®-FRESH and HYLO- FORTE® eye drops to the Australasian market.

These preservative-free and phosphate-free eye drops are delivered in a unique medical device that provides an ingenious new solution for the treatment of dry eye, severe and chronic cases of dry eye, or post-surgery.

The patented COMOD® bottle is an air-less multi-dose application system that ensures the precise delivery of at least 300 sterile and preservative-free drops in each 10ml pack. HYLO®-FRESH utilises high quality sodium hyaluronate (0.1%) to provide effective and long-lasting lubrication for dry eyes of moderate to medium severity.

HYLO-FORTE® is formulated with an elevated concentration of sodium hyaluronate (0.2%) producing a high viscosity product that provides more intensive lubrication of severe or chronic cases of dry eye, without vision impairment. It is also suitable for use following surgery. HYLO®- FRESH and HYLO-FORTE® eye drops both have a use-up period of six months after opening, and are compatible with all contact lenses.

November 28, 2025

AFT Pharmaceuticals SA acquires the Hospital Division of Pharma Dynamics

AFT Pharmaceuticals SA (Pty) Ltd (‘AFT SA’) announces it has successfully completed the acquisition of the Hospital Division business of Pharma Dy…

Read More

November 20, 2025

AFT delivers 10th consecutive first half revenue increase

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…

Read More

November 12, 2025

AFT Pharmaceuticals Brings Next-Generation Liposomal Collagen and Wellness Range to the U.S. Market 

AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…

Read More